Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has shared an announcement.
Daito Pharmaceutical reported consolidated net sales of ¥25.14 billion for the six months ended November 30, 2025, up 2.3% year on year, with operating profit rising 10.6% to ¥1.63 billion and profit attributable to owners of parent jumping 35.8% to ¥1.23 billion, indicating an improvement in profitability despite only modest top-line growth. The company’s financial position remained solid with an equity ratio of 67.9%, and it maintained its full‑year forecast for fiscal 2026, targeting 3.7% sales growth and a 20.5% increase in net profit, while planning total annual dividends of ¥40 per share post–stock split, underscoring a continued commitment to shareholder returns and suggesting steady operational performance in a challenging pharmaceutical market.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1291.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd., listed on the Tokyo Stock Exchange under securities code 4577, operates in the pharmaceutical industry, developing and manufacturing drug products and related healthcare offerings for the domestic market. The company targets stable, long‑term growth in ethical and other pharmaceutical segments, with a focus on profitability and capital efficiency as reflected in its dividend and earnings policies.
Average Trading Volume: 65,828
Technical Sentiment Signal: Buy
Current Market Cap: Yen41.01B
See more data about 4577 stock on TipRanks’ Stock Analysis page.